Efficacy of Treatment With the Tyrosine Kinase 2 Inhibitor Zasocitinib in Patients With Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
JAMA Dermatol 2024 Aug 21;[EPub Ahead of Print], AW Armstrong, M Gooderham, C Lynde, C Maari, S Forman, L Green, V Laquer, X Zhang, N Franchimont, EA Gangolli, J Blau, Y Zhao, W Zhang, B Srivastava, G Heap, K PappFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.